Alar Pharmaceuticals (ROCO:6785) Cash Flow for Dividends: NT$0.00 Mil (TTM As of Dec. 2025)


ROCO:6785 Alar Pharmaceuticals Inc ROCO:6785
52 GF Score
Price NT$117.00
GF Value NT$90.64
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is Alar Pharmaceuticals Cash Flow for Dividends?

Alar Pharmaceuticals ROCO:6785 52 Cash Flow for Dividends is NT$0.00 Mil as of Dec. 2025. GuruFocus rates ROCO:6785 with a GF Score™ of 52/100 and a GF Value™ of NT$90.64 (Modestly Overvalued). The stock has 1 warning sign investors should review.

Alar Pharmaceuticals's cash flow for dividends for the three months ended in Dec. 2025 was NT$0.00 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.00 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Alar Pharmaceuticals's annual payment of dividends increased from Dec. 2023 (NT$0.00 Mil) to Dec. 2024 (NT$-100.20 Mil) but then declined from Dec. 2024 (NT$-100.20 Mil) to Dec. 2025 (NT$-16.70 Mil).

Alar Pharmaceuticals Cash Flow for Dividends Related Terms

Alar Pharmaceuticals Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Alar Pharmaceuticals's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alar Pharmaceuticals Cash Flow for Dividends Chart

Alar Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 -100.20 -16.70

Alar Pharmaceuticals Quarterly Data
Jun20 Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ROCO:6785
52GF Score
Alar Pharmaceuticals Inc ROCO:6785
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alar Pharmaceuticals Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of NT$0.00 Mil mean?
Alar Pharmaceuticals (ROCO:6785) has a Cash Flow for Dividends of NT$0.00 Mil as of Dec. 2025. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Alar Pharmaceuticals and its competitors.
Is Alar Pharmaceuticals' Cash Flow for Dividends too high?
Alar Pharmaceuticals' current Cash Flow for Dividends is NT$0.00 Mil. Overall, Alar Pharmaceuticals has a GF Score™ of 52/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alar Pharmaceuticals' Cash Flow for Dividends compare to ZTS and UTHR?
Alar Pharmaceuticals' Cash Flow for Dividends of NT$0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Drug Manufacturers company?
A good Cash Flow for Dividends depends on the Drug Manufacturers industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Alar Pharmaceuticals and its competitors. Alar Pharmaceuticals's current Cash Flow for Dividends is NT$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alar Pharmaceuticals (ROCO:6785) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$90.64, compared to a current price of NT$117.00 — trading 29.1% above its estimated fair value. The current Cash Flow for Dividends is NT$0.00 Mil. Alar Pharmaceuticals' overall GF Score™ is 52/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Alar Pharmaceuticals (ROCO:6785), the current Cash Flow for Dividends is NT$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alar Pharmaceuticals (ROCO:6785) Overvalued in 2026?

Based on GuruFocus' analysis, Alar Pharmaceuticals stock appears to be overvalued. The current stock price of NT$117.00 is trading 29.1% above its estimated GF Value™ of NT$90.64. GuruFocus considers Alar Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for ROCO:6785:

  • Cash Flow for Dividends: NT$0.00 Mil
  • GF Value™: NT$90.64 vs. price of NT$117.00 (29.1% above fair value)
  • GF Score™: 52/100 with 1 warning sign

No single metric tells the full story. See the ROCO:6785 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alar Pharmaceuticals Business Description

Address Jhongke Road, No. 32, No. 2, 5th Floor, Situn District, Taichung, TWN, 428015
Alar Pharmaceuticals Inc is a drug development company mainly engaged in the research and development of new drugs, sales of western pharmaceuticals, and medical devices. It focuses on developing long-acting release drug products for CNS disorders and chronic diseases, which mainly include opioid use disorder, chronic pain, and depressive disorder. The company currently has only a new drug development division, and its product pipeline comprises various drug candidates such as ALA-1000 (Buprenorphine), ALA-1300, ALA-2000 (Naltrexone), ALA-3000 (Ketamine), ALA-4000 (Apomorphine), and ALA-5000 (Third-generation antipsychotic). Geographically, the company generates maximum revenue from the USA and also has its presence in Taiwan and the United Kingdom.
52GF Score

Get the complete analysis for ROCO:6785

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$117.00
Price
NT$90.64
GF Value